Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397691 | 0.84 | RAB9A (0.55) | GAAPKMRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13233307 | 0.83 | MAPT (0.59) | MEN1KMT2AGAAPKMRAB9A | |
| SCHEMBL19214776 | 0.82 | NPC1 (0.54) | GAAPKMRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1059693 | 0.81 | RAB9A (0.64) | GAAPKMRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29087538 | 0.80 | MAPT (0.56) | GAAPKMRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL757031 | 0.79 | RAB9A (0.62) | MEN1KMT2AGAAPKMRAB9A | |
| SCHEMBL30037937 | 0.79 | RAB9A (0.62) | MEN1KMT2AGAAPKMRAB9A | |
| SCHEMBL15978916 | 0.79 | MEN1 (0.68) | MEN1KMT2AGAAPKMRAB9A | |
| SCHEMBL26622829 | 0.79 | PKM (0.68) | MEN1KMT2AGAAPKMRAB9A | |
| SCHEMBL12776009 | 0.79 | KMT2A (0.72) | MEN1KMT2AGAAPKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230339972-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339972-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339971-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
| US-7932257-B2 | Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7601725-B2 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-7408025-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | MEN1 2026/4885KMT2A 186/4885GAA 4034/4885 |
| US-20230339971-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DHFR | MEN1 3374/4885KMT2A 3151/4885GAA 1146/4885 |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | MEN1 4641/4885KMT2A 2066/4885GAA 553/4885 |
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | MEN1 3652/4885KMT2A 1612/4885GAA 2982/4885 |
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | AURKA, AURKB, AURKC | MEN1 1102/4885KMT2A 529/4885GAA 2817/4885 |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | MEN1 4641/4885KMT2A 2066/4885GAA 553/4885 |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | AURKA, AURKB, AURKC | MEN1 1380/4885KMT2A 622/4885GAA 3181/4885 |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE12, PDE4A | MEN1 2891/4885KMT2A 1451/4885GAA 678/4885 |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | SDHA, SDHB, DPYD | MEN1 3100/4885KMT2A 3060/4885GAA 1265/4885 |
| US-20230339972-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | MEN1 3100/4885KMT2A 3060/4885GAA 1265/4885 |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | MEN1 2476/4885KMT2A 1713/4885GAA 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.